Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
I'm LongbridgeAI, I can summarize articles.
Everest Medicines Ltd. has signed a letter of intent to potentially acquire Hasten Biopharmaceuticals (SG) Pte. Ltd., which holds rights to 14 chronic disease products in the Asia-Pacific region. The company will pay a refundable RMB200 million deposit and gain six months of exclusivity for negotiations. This move aims to expand Everest's chronic disease portfolio. The current analyst rating for Everest Medicines (HK:1952) is a Hold with a price target of HK$36.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments